Industry: Healthcare | Publish Date: 28-Oct-2024 | No of Pages: 139 | No. of Tables: 104 | No. of Figures: 69 | Format: PDF | Report Code : HC2368
The Africa In-Vitro Diagnostics Market size was valued at USD 0.93 billion in 2023, and is predicted to reach USD 1.45 billion by 2030, at a CAGR of 6 % from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions.
IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology. These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.
Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.
In Ghana, the in-vitro diagnostics market is showing a steady growth due to investments allocated by various organizations to improve healthcare services. In 2022, the World Bank sanctioned USD 150 million in support for the Primary Health Care Investment Program. With a particular emphasis on healthcare investment, the funding intends to strengthen the quality and accessibility of primary health care services in Ghana.
This strategic investment is poised to drive the Africa in-vitro diagnostics market growth by fostering a conducive environment for healthcare innovation and infrastructure development.
By strengthening primary health care systems, including diagnostic facilities, the initiative enhances the capacity to diagnose and manage diseases effectively, thereby boosting the demand for in-vitro diagnostics in the region.
The alarming rate of heart diseases in South Africa drives the demand for advanced diagnostics solutions such as in-vitro diagnostics. As reported by the Heart & Stroke Foundation, the country witnesses 215 deaths from heart disease or strokes each day.
Moreover, every hour, 5 individuals experience heart attacks, while 10 suffer from strokes. This concerning scenario underscores the urgent need for early detection and diagnosis of cardiovascular diseases. IVD enables early detection by identifying cardiac biomarkers associated with heart disease, allowing for intervention before symptoms manifest.
Additionally, immunodiagnostic tests assess individual cardiovascular risk factors, guiding tailored preventive strategies and for diagnosed patients. In-vitro diagnostics facilitates disease monitoring, ensuring timely adjustments to treatment plans for optimal outcomes.
High costs associated with research, development, and regulatory approval are significant factors restraining the Africa IVD market expansion. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability.
Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.
Point-of-care testing (POCT) is poised to significantly drive the Africa IVD market demand, in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.
With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.
The promising players operating in the Africa in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.
Reagents
Instruments
Software & Services
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Rapid Tests
Chemiluminescence Immunoassay (CLIA)
Enzyme-linked Immunosorbent spot (ELISpot)
Radioimmunoassay (RIA)
Western Blot
Hematology
Molecular Diagnostics
PCR
INAAT
Hybridization
DNA diagnostics
Microarray
Other Molecular Diagnostics
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Renal Profile
Lipid Profile
Thyroid Function Panel
Electrolyte Panel
Speciality Chemicals
Other IVD Techniques
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others
Stand Alone Laboratory
Hospitals
Academics and Medical Schools
Point of Care Testing
Other End Users
Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.
REPORT SCOPE AND SEGMENTATION:
Parameters |
Details |
Market Size Value in 2023 |
USD 0.93 billion |
Revenue Forecast in 2030 |
USD 1.45 billion |
Value Growth Rate |
CAGR of 6.0% from 2024 to 2030 |
Analysis Period |
2023–2030 |
Base Year Considered |
2023 |
Forecast Period |
2024–2030 |
Market Size Estimation |
Billion (USD) |
Growth Factors |
|
Companies Profiled |
10 |
Customization Scope |
Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and Purchase Options |
Avail customized purchase options to meet your exact research needs. |